Viking Therapeutics Inc. (VKTX)
Viking Therapeutics, Inc. (VKTX) Q3 2025 Earnings Call Transcript
Viking Therapeutics, Inc. (NASDAQ:VKTX ) Q3 2025 Earnings Call October 22, 2025 4:30 PM EDT Company Participants Brian Lian - President, CEO & Director Gregory Zante - Chief Financial Officer Conference Call Participants Stephanie Diaz - Vida Strategic Partners, Inc. Steven Seedhouse - Cantor Fitzgerald & Co., Research Division Joon Lee - Truist Securities, Inc., Research Division Ryan Deschner - Raymond James & Associates, Inc., Research Division Annabel Samimy - Stifel, Nicolaus & Company, Incorporated, Research Division Hardik Parikh - JPMorgan Chase & Co, Research Division Jay Olson - Oppenheimer & Co. Inc., Research Division Mayank Mamtani - B. Riley Securities, Inc., Research Division Rohit Bhasin - Morgan Stanley, Research Division Yale Jen - Laidlaw & Company (UK) Ltd.
Viking Therapeutics, Inc. (VKTX) Stock Dips While Market Gains: Key Facts
In the closing of the recent trading day, Viking Therapeutics, Inc. (VKTX) stood at $33.54, denoting a -3.44% move from the preceding trading day.
Pre-Q3 Earnings: Is Viking Therapeutics Stock a Portfolio Must-Have?
VKTX is likely to have headed into Q3 earnings with no product revenue, pipeline updates in focus and widening loss forecasts testing investor patience.
Viking Therapeutics, Inc. (VKTX) Registers a Bigger Fall Than the Market: Important Facts to Note
Viking Therapeutics, Inc. (VKTX) closed at $33.05 in the latest trading session, marking a -2.54% move from the prior day.
Viking Therapeutics: A Speculative Buy
Viking Therapeutics offers a de-risked, asymmetric investment opportunity in the GLP-1 weight-loss drug market, trading below its risk-adjusted potential. VKTX's injectable and oral VK2735 both met Phase 2 endpoints, with discontinuation issues in the oral form likely fixable through slower titration and different dosing. Strong cash reserves, committed manufacturing partner, and a diversified pipeline (including VK2809 for MASH) position VKTX for long-term value creation or strategic or financial buyout/going private.
Viking Therapeutics, Inc. (VKTX) Beats Stock Market Upswing: What Investors Need to Know
In the closing of the recent trading day, Viking Therapeutics, Inc. (VKTX) stood at $27.88, denoting a +1.86% move from the preceding trading day.
Viking Therapeutics, Inc. (VKTX) Stock Falls Amid Market Uptick: What Investors Need to Know
Viking Therapeutics, Inc. (VKTX) reached $24.09 at the closing of the latest trading day, reflecting a -2.92% change compared to its last close.
Wall Street Bulls Look Optimistic About Viking Therapeutics (VKTX): Should You Buy?
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Viking Therapeutics Loses 20% in a Month: How to Play the Stock
VKTX stock slumps after mixed obesity pill study results raise safety concerns and highlight fierce market competition.
Viking Therapeutics, Inc. (VKTX) Suffers a Larger Drop Than the General Market: Key Insights
Viking Therapeutics, Inc. (VKTX) reached $27.05 at the closing of the latest trading day, reflecting a -1.92% change compared to its last close.
Viking Therapeutics: Panic Creates Opportunity
Viking Therapeutics' stock plunged over 40% after misunderstood Phase 2 oral weight-loss drug data, despite results showing strong short-term efficacy versus market leaders. The Phase 2 trial demonstrated 12.2% weight loss in 13 weeks, with progressive results and potential for further improvement with longer dosing periods. Concerns over high discontinuation and GI side effects are noted, but these issues are manageable and expected to be addressed in Phase 3 studies.
Wall Street Analysts Think Viking Therapeutics (VKTX) Is a Good Investment: Is It?
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
